Senior executives from artificial intelligence-driven biotechnology firm Insilico Medicine are scheduled to participate in a series of biopharma and technology conferences across China and the UAE in November 2026, according to News-Medical.
In China, Dr. Jue Wang, Head of Global Business Development at Insilico Medicine, will deliver a keynote speech on navigating AI commoditization at the China Healthcare Summit in Shanghai on November 3. The company is also scheduled to exhibit at the China International Import Expo in Shanghai from November 5 to 10, while Co-CEO and Chief Scientific Officer Dr. Feng Ren will attend healthcare investment and medicinal chemistry conferences in Shanghai and Nanchang.
In Dubai, Dr. Alex Aliper, Co-Founder and President of Insilico Medicine, will attend the Next Generation Medicine Congress 2026 held from November 7 to 10. On November 7, Dr. Aliper will speak on an investor and innovator panel, addressing how AI biotechs demonstrate durable platform capabilities, closed-loop wet-lab validation, and reproducible pipelines to investors. The Dubai congress will bring together more than 60 speakers from over 20 countries.
Insilico Medicine reported nominating 11 preclinical candidates during the first 10 months of 2026, bringing its cumulative count since 2021 to 35 candidates. The company also noted achieving eight clinical milestones across internal and partnered pipelines as of mid-August 2026.
Sources
- News-Medical · 2026-10-30
